NYSE · GILD
Healthcare · Drug Manufacturers - General
$146.30
Down-$0.11 (-0.08%)
Updated Sep 16, 2026, 10:47 AM
SID Score
7.3/10
Composite research score
Smart Money
44/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GILD closed at $146.30 after 20 trading sessions, up 1.99% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $144.002 | $146.35 | $142.94 | $146.30 | 4.54M |
| Sep 14, 2026 | $144.26 | $146.75 | $143.71 | $146.41 | 4.92M |
| Sep 11, 2026 | $145.24 | $145.99 | $143.50 | $143.72 | 4.2M |
| Sep 10, 2026 | $145.07 | $145.9066 | $143.67 | $144.81 | 6.02M |
| Sep 9, 2026 | $145.46 | $147.68 | $145.00 | $145.65 | 4.58M |
| Sep 8, 2026 | $146.98 | $148.6491 | $145.45 | $146.64 | 6.08M |
| Sep 4, 2026 | $149.23 | $151.185 | $149.23 | $150.995 | 6.18M |
| Sep 3, 2026 | $150.67 | $151.48 | $148.41 | $151.22 | 4.5M |
| Sep 2, 2026 | $150.00 | $152.55 | $148.83 | $149.61 | 4.92M |
| Sep 1, 2026 | $148.52 | $149.96 | $146.915 | $149.92 | 4.87M |
| Aug 31, 2026 | $144.23 | $147.22 | $143.175 | $146.34 | 6.59M |
| Aug 28, 2026 | $149.47 | $149.47 | $144.88 | $145.68 | 3.95M |
| Aug 27, 2026 | $147.30 | $149.105 | $146.01 | $148.86 | 5.01M |
| Aug 26, 2026 | $148.00 | $149.6199 | $147.004 | $148.09 | 5.26M |
| Aug 25, 2026 | $146.60 | $148.94 | $145.58 | $148.77 | 4.63M |
| Aug 24, 2026 | $145.93 | $146.835 | $144.59 | $146.74 | 6.18M |
| Aug 21, 2026 | $144.52 | $147.905 | $143.50 | $146.12 | 5.38M |
| Aug 20, 2026 | $146.69 | $146.82 | $143.19 | $143.44 | 7.17M |
| Aug 19, 2026 | $145.10 | $148.97 | $144.30 | $147.60 | 6.74M |
| Aug 18, 2026 | $140.00 | $143.89 | $139.54 | $143.44 | 5.76M |
The latest Smart Investors Daily articles mentioning GILD.
GILD research
Company profile and research snapshot.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Buy | — |
| Aug 5, 2026 | RBC Capital | Sector Perform | — |
| Aug 5, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 5, 2026 | Needham | Buy | — |
| Jul 29, 2026 | Barclays | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead’s HIV medication for the […]
Benzinga · Sep 10, 2026
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.42% on an annualized basis producing an average annual return of 11.56%. Currently, Gilead Sciences has a market capitalization of
Yahoo · Sep 10, 2026
Gilead Sciences (NASDAQ:GILD) CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment businesses, while advancing programs in inflammation, oncology and cell therapy. Dickinson said the
SeekingAlpha · Sep 10, 2026
Gilead Sciences, Inc. (GILD) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 10:55 AM EDTCompany ParticipantsAndrew Dickinson...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GILD.
